# Ipsen Announces Two Oncology and Immunology Acquisitions Worth at Least $670 Million

> ma · REPORTED · 2026-07-02

Ipsen struck two separate deals worth a combined minimum of $670 million, including a planned acquisition of Kartos Therapeutics to gain a late-stage MDM2 blocker for myelofibrosis as an add-on to ruxolitinib. The deals reinforce that late-stage cancer and immune system assets remain among the most coveted targets in biopharma M&A.

- Company: Ipsen
- Sector: oncology
- Primary source: https://www.biopharmadive.com/

---
Source: MedFuel Intel news monitor. Verification tier: REPORTED. Informational only, not investment advice. Corrections: media@medfuelinc.com.